Overview

 

ExCellThera is a clinical stage biotechnology company delivering molecules and bioengineering solutions to expand blood stem and immune cells for therapeutic use. ExCellThera’s lead technology, ECT-001, combines a proprietary small molecule, UM171, and an optimized culture system. In pursuit of better treatments for patients, the company is building out its portfolio of products, as well as supporting best-in-class clinical trials.

Investors

Investors

Any inquiries relating to potential investment in ExCellThera can be directed to David Millette, CFO, CLO.

Partnering

ExCellThera's innovative stem cell therapies are not yet available to patients. To learn more about our approach to treating disease, please visit Our Platform.

In an effort to explore the clinical possibilities of its highly innovative solutions, ExCellThera is pursuing research and development collaborations including platform, product and academic collaborations. If you are interested in partnering with ExCellThera please contact David Millette, CFO & CLO.

Patients

Patients

ExCellThera’s innovative stem cell therapies are currently in clinical trials. To learn more about our approach to treating disease, please visit Our Solution.

Partners